AN2 Therapeutics Secures $12M Series A Financing and Enters Strategic Partnership with Brii Biosciences

On November 21, 2019, VCBeat (WeChat ID: vcbeat) learned from foreign media that biopharmaceutical company AN2 Therapeutics announced it had secured $12 million in Series A financing. The round was led by Mountain Group Partners, with participation from Adjuvant Capital, Brii Biosciences, and BioRock Ventures.

It is reported that AN2 Therapeutics intends to use these funds to advance its lead clinical-stage program, which involves therapeutic agents with novel mechanisms of action, as well as multiple early-stage programs.

AN2 Therapeutics is a global health biopharmaceutical company headquartered in California, dedicated to leveraging modern biomedical and drug development expertise to deliver translational therapies for patients with infectious diseases.

Eric Easom, Co-founder and CEO of AN2 Therapeutics, stated, “We have the opportunity to advance a new initiative alongside a distinguished group of investors, management team members, and scientists who strongly support AN2 Therapeutics’ mission to improve the lives of patients with infectious diseases worldwide through drug development. To address global health challenges without compromising our business objectives, we intend to leverage strategic partnerships and non-dilutive funding to expand the company’s global public health programs.”

Rob Readnour, Managing Director of MGP, stated: “The evolving public health challenges of the future require us to increase investment in new drug development to address the significant needs of patients worldwide. Current treatment regimens for high-burden diseases are often decades old, with suboptimal safety and efficacy profiles. AN2’s novel and leading drug candidates and foundational platform can simultaneously meet the needs of patients in both high-value and underserved markets, creating a true win-win situation.”

AN2 Therapeutics also announced a strategic partnership with Brii Biosciences, a clinical-stage biotechnology company dedicated to meeting patient needs and improving public health in China and globally. Under the terms of the agreement, Brii Biosciences will be licensed to develop, manufacture, and commercialize AN2 Therapeutics’ leading clinical-stage antimicrobial compound in Greater China.

Easom added, “It is an honor to collaborate with Brii Biosciences and its world-class team of scientists in the field of infectious diseases. We look forward to pooling our collective strengths to serve patients suffering from infectious diseases.”

Mountain Group Partners (MGP) is a leading venture capital firm dedicated to investing in the early stages of startups in the life sciences sector. Founded in 2002, MGP has invested in more than 50 companies to date.

Adjuvant Capital is a life sciences investment firm focused on global health. Established in 2012, the fund primarily invests in innovative technology companies addressing high-burden and neglected infectious diseases, as well as maternal, reproductive, and sexual health.

(Compiled by Xiong Hui)